Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Panax notoginseng Tablets (PSQ project) is an innovative Traditional Chinese Medicine (TCM) Category 1.1 candidate developed by Yunnan Baiyao Group. Formulated as an oral tablet, the drug is derived from the roots of *Panax notoginseng* and is indicated for cardiovascular symptoms such as chest tightness, heart pain, palpitations, and dizziness caused by blood stasis in the heart veins. It is also being evaluated for the prevention of cardiovascular events in middle-aged and elderly patients. The project has completed Phase 2 clinical trials involving 704 cases and has finalized its pharmaceutical research phase.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Panax notoginseng Tablets.